Format

Send to

Choose Destination
Gastroenterol Hepatol (N Y). 2011 Jul;7(7):455-93.

Antibiotics for the treatment of irritable bowel syndrome.

Author information

1
Dr. Basseri, Ms. Weitsman, and Dr. Barlow are affiliated with the GI Motility Program at Cedars-Sinai Medical Center in Los Angeles, California, where Dr. Pimentel serves as Director.

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with an estimated worldwide prevalence of 10-20%. IBS can be associated with severe gastrointestinal symptoms, including abdominal pain, bloating, and altered bowel function. Although the causes of IBS remain undefined, recent research has increasingly suggested roles for gut flora in IBS. These roles involve postinfectious IBS, which can occur after a single episode of acute gastroenteritis, and small intestinal bacterial overgrowth, in which elevated populations of aerobic and anaerobic bacteria cause abdominal pain and altered bowel function. More recently, potential roles for methanogens in contributing to IBS subtypes have also been identified. In this paper, we review the different mechanisms by which gut flora may contribute to IBS and also discuss the efficacy and safety of various antibiotic therapies for treating IBS symptoms.

KEYWORDS:

Irritable bowel syndrome; antibiotics; neomycin; re-treatment; rifaximin

PMID:
22298980
PMCID:
PMC3264894

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center